{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:35:58Z","timestamp":1791639358366,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We present a case in which vancomycin and dalbavancin exposure preceded emergence of nonsusceptibility to dalbavancin, vancomycin, and daptomycin in a strain of methicillin-resistant Staphylococcus aureus in the setting of a left ventricular assist device (LVAD) infection. We characterized 6 related but genetically unique isolates collected over more than 1 year of recurrent therapy and found that the most resistant isolate acquired multiple walK-related mutations, which has been previously implicated in dalbavancin resistance with vancomycin and daptomycin cross-resistance. Using time-kills at subinhibitory exposures, we found that cefadroxil is synergistic with dalbavancin against the susceptible and resistant strains. This is the first report of dalbavancin nonsusceptibly associated with an LVAD infection, but dalbavancin resistance has been documented previously in association with treatment of endovascular infections. Combination therapy with synergistic and orally bioavailable agents like cefadroxil may be a reasonable strategy to enhance activity and possibly diminish emergence of resistance to dalbavancin.<\/jats:p>","DOI":"10.1093\/ofid\/ofag074","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:44:08Z","timestamp":1770986648000},"source":"Crossref","is-referenced-by-count":3,"title":["Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8324-6414","authenticated-orcid":false,"given":"Erica J","family":"Stohs","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Creighton University Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-2569","authenticated-orcid":false,"given":"Bryan T","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical & Nutrition Care, Nebraska Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-6884","authenticated-orcid":false,"given":"Paul D","family":"Fey","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie C L","family":"Foreman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-5200","authenticated-orcid":false,"given":"Libin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1454-6381","authenticated-orcid":false,"given":"Kelsi","family":"Penewit","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5202-1108","authenticated-orcid":false,"given":"Adam","family":"Waalkes","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-6992","authenticated-orcid":false,"given":"Stephen J","family":"Salipante","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-4098","authenticated-orcid":false,"given":"Brian J","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026031116101635800_ofag074-B1","doi-asserted-by":"publisher","first-page":"ofz235","DOI":"10.1093\/ofid\/ofz235","article-title":"Left ventricular assist device infections and the potential role for dalbavancin: a case report","volume":"6","author":"Howard-Anderson","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026031116101635800_ofag074-B2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/1120009X.2022.2136426","article-title":"Dalbavancin as chronic antibiotic suppression therapy for left ventricular assist device driveline infection due to methicillin-resistant Staphylococcus aureus: a case report","volume":"35","author":"Pallotto","year":"2023","journal-title":"J Chemother"},{"key":"2026031116101635800_ofag074-B3","doi-asserted-by":"crossref","first-page":"15515","DOI":"10.1038\/s41598-025-99112-7","article-title":"Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus","volume":"15","author":"Morath","year":"2025","journal-title":"Sci Rep"},{"key":"2026031116101635800_ofag074-B4","doi-asserted-by":"publisher","first-page":"ofad537","DOI":"10.1093\/ofid\/ofad537","article-title":"Long-term dalbavancin for suppression of gram-positive chronic left ventricular assist device infections","volume":"10","author":"Rowe","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026031116101635800_ofag074-B5","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2026031116101635800_ofag074-B6","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin non-susceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization","volume":"75","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031116101635800_ofag074-B7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"2026031116101635800_ofag074-B8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2026031116101635800_ofag074-B9","doi-asserted-by":"crossref","first-page":"688357","DOI":"10.3389\/fmolb.2021.688357","article-title":"Synergy between beta-lactams and lipo-, glyco-, and lipoglycopeptides, is independent of the seesaw effect in methicillin-resistant Staphylococcus aureus","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026031116101635800_ofag074-B10","first-page":"82","article-title":"Evaluation of dalbavancin alone and in combination with beta-lactam antibiotics against resistant phenotypes of Staphylococcus aureus","volume":"74","author":"Xhemali","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031116101635800_ofag074-B11","doi-asserted-by":"crossref","first-page":"e01743-18","DOI":"10.1128\/AAC.01743-18","article-title":"Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic\/pharmacokinetic model","volume":"63","author":"Kebriaei","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101635800_ofag074-B12","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically","author":"Clinical Laboratory Standards Institute","year":"2023"},{"key":"2026031116101635800_ofag074-B13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2026031116101635800_ofag074-B14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/JCM.03385-14","article-title":"Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology","volume":"53","author":"Salipante","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2026031116101635800_ofag074-B15","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1099\/mic.0.2007\/011874-0","article-title":"Novick, agr function in clinical Staphylococcus aureus isolates","volume":"154","author":"Traber","year":"2008","journal-title":"Microbiology"},{"key":"2026031116101635800_ofag074-B16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/AAC.21.2.320","article-title":"Pharmacokinetics of cefadroxil after oral administration in humans","volume":"21","author":"La Rosa","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101635800_ofag074-B17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drup.2013.10.002","article-title":"Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the \u201cseesaw effect\u201d: taking advantage of the back door left open?","volume":"16","author":"Ortwine","year":"2013","journal-title":"Drug Resist Updat"},{"key":"2026031116101635800_ofag074-B18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbagen.2005.09.002","article-title":"Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains","volume":"1726","author":"Wootton","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"2026031116101635800_ofag074-B19","doi-asserted-by":"crossref","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","article-title":"Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus","volume":"27","author":"Werth","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026031116101635800_ofag074-B20","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1128\/AAC.00437-10","article-title":"An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus","volume":"54","author":"Cui","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101635800_ofag074-B21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.00039-06","article-title":"Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus","volume":"50","author":"Friedman","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101635800_ofag074-B22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"},{"key":"2026031116101635800_ofag074-B23","doi-asserted-by":"crossref","first-page":"1185602","DOI":"10.3389\/fphar.2023.1185602","article-title":"Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety","volume":"14","author":"Ruiz-Sancho","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026031116101635800_ofag074-B24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/antibiotics12111639","article-title":"Long-term suppressive therapeutic-drug-monitoring-guided dalbavancin therapy for cardiovascular prosthetic infections","volume":"12","author":"Gallerani","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026031116101635800_ofag074-B25","doi-asserted-by":"publisher","first-page":"ofaf260","DOI":"10.1093\/ofid\/ofaf260","article-title":"Bridging to transplant: TDM-guided outpatient dalbavancin therapy in chronic granulomatous disease with deep-seeded inoperable abscesses over 11 months","volume":"12","author":"Banz","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026031116101635800_ofag074-B26","doi-asserted-by":"crossref","first-page":"e0183024","DOI":"10.1128\/aac.01830-24","article-title":"Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections","volume":"69","author":"Cojutti","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101635800_ofag074-B27","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/jac\/dkz562","article-title":"Occurrence of cross-resistance and beta-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels","volume":"75","author":"Hines","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031116101635800_ofag074-B28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2026031116101635800_ofag074-B29","doi-asserted-by":"crossref","first-page":"E1710","DOI":"10.1073\/pnas.1522179113","article-title":"ppGpp negatively impacts ribosome assembly affecting growth and antimicrobial tolerance in gram-positive bacteria","volume":"113","author":"Corrigan","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031116101635800_ofag074-B30","doi-asserted-by":"crossref","first-page":"20420","DOI":"10.7554\/eLife.20420","article-title":"Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment","volume":"6","author":"Gomez","year":"2017","journal-title":"Elife"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag074\/66956834\/ofag074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag074\/66956834\/ofag074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag074\/66956834\/ofag074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:10:28Z","timestamp":1773259828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag074\/8488423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag074","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,16]]},"article-number":"ofag074"}}